Adial Pharmaceuticals 收到美国专利商标局 （USPTO） 的 AUD 药品专利许可通知。 Adial Pharmaceuticals receives Notice of Allowance for an AUD drug patent from USPTO.

Adial制药公司收到了美国专利和商标局颁发的新专利津贴通知,加强了AD04的知识产权,AD04是治疗酗酒紊乱的药物。 Adial Pharmaceuticals Inc. has received a Notice of Allowance for a new patent from the U.S. Patent and Trademark Office, enhancing its intellectual property for AD04, a drug aimed at treating alcohol use disorder (AUD). 该专利涵盖其遗传诊断工具确认的其他基因型组合,支持精密医学方法。 The patent covers additional genotype combinations identified by its genetic diagnostic tool, supporting a precision medicine approach. 预计ONWARD 3期试验的总体结果将在2024年第四季度发布. Topline results from the ONWARD Phase 3 trial are expected in the fourth quarter of 2024.